Inovio Pharmaceuticals, Inc.

INO

$1.27

-1.55%

2026-08-31 16:00:01 EDT-$0.02

Healthcare

Biotechnology

NASDAQ

Active Trading

Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is ...

Price Action of INO

$1.27

-1.55%-$0.02

High—

Low—

52W High-57.4%

Rel. vol—

Interval

Range6.3h

Volume—SMA5SMA10

—

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) is a clinical-stage biotechnology company headquartered in Plymouth Meeting, Pennsylvania, dedicated to advancing DNA medicines to help save and protect lives worldwide. The company was founded in 1999 and employs approximately 112 people as of the latest data. Inovio's core technology platform leverages precisely engineered ...Inovio Pharmaceuticals, Inc. (NASDAQ: INO) is a clinical-stage biotechnology company headquartered in Plymouth Meeting, Pennsylvania, dedicated to advancing DNA medicines to help save and protect lives worldwide. The company was founded in 1999 and employs approximately 112 people as of the latest data. Inovio's core technology platform leverages precisely engineered SynCon DNA plasmids to design and optimize antigens for a broad range of diseases. This is delivered using its proprietary CELLECTRA smart device, which uses electroporation to enhance cellular uptake of the DNA vaccines. Inovio's pipeline is robust, focusing on HPV-related diseases such as cervical, vulvar, and anal dysplasia, as well as HPV-driven cancers of the head and neck, cervix, anus, penis, vulva, and vagina. Its lead candidate, INO-3107, is being developed for the treatment of recurrent respiratory papillomatosis (RRP), a rare and debilitating disease. The company also has programs for glioblastoma multiforme, prostate cancer, and infectious diseases like HIV, Ebola, MERS, and Lassa fever. During the COVID-19 pandemic, Inovio developed INO-4800, an investigational DNA vaccine, which has been partnered with the International Vaccine Institute and Seoul National University Hospital. The company collaborates with a wide range of partners, including AstraZeneca, The Bill & Melinda Gates Foundation, CEPI, DARPA, NIH, Regeneron, and the University of Pennsylvania. These partnerships provide funding, research support, and development capabilities. Financially, Inovio is a clinical-stage company with no approved products, resulting in no revenue. It reported a market cap of approximately $52.9 million as of the latest data, with a negative enterprise value. The company has significant cash burn, with an operating cash flow of -$1.206 per share, and relies on equity financing and partnerships to fund operations. As of the latest quarter, the company had a current ratio of 1.04, indicating adequate short-term liquidity, but its long-term viability depends on successful clinical development and potential partnerships or licensing deals. Key leadership includes CEO Dr. Jacqueline Shea, who has served since May 2022, and the company has a history of leadership changes and strategic pivots. Inovio's vision is to transform the treatment and prevention of diseases through innovative DNA-based solutions, and it continues to advance its clinical programs with the hope of bringing life-saving therapies to market.ExpandCollapse

Founded

1999

Employees

112

CEO

Jacqueline E. Shea

Full Name

Inovio Pharmaceuticals, Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

-1005.80%

Market Cap

$0.09B

Current Ratio

1.00

WACC

10.75%

ROIC

-892.20%

Contact Information

https://www.inovio.com

267 440 4200

660 West Germantown Pike, Plymouth Meeting, PA 19462

Key Metrics of INO

Snapshot

Latest / TTM · 6 periods

Market Cap

$87.75M

ROCE

-836.6%

EV / EBITDA

-1.09x

-553.2% YoY

FCF Yield

-86.0%

+23.0% YoY

Cash Conversion Cycle

-2836.5d

Current Ratio

1.00

Quick take

TTM —

Current ratio below 1.0

Negative working capital

Financial Highlights of INO

Profitability trend

Latest / TTM · 6 periods

Gross Margin

0.0%

Net Margin

0.0%

P/E Ratio

-1.17x

n/a

Debt / Equity

1.83

n/a

Current Ratio

1.00

Dividend Yield

0.0%

Understanding

TTM —

Current ratio below 1.0

Interest coverage is weak

Calendar of INO

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.20 · Revenue $2.27M · 2 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.18 · Revenue $666667.00 · 2 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-0.76 · Revenue $666667.00 · 2 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-0.17 · Revenue $6.90M · 1 analysts

Recent history

Aug 12, 2026
Q2 FY2026 · Results reported
EPS $-0.07 · Revenue $0.00
View filing
May 13, 2026
Q1 FY2026 · Results reported
EPS $-0.28 · Revenue $0.00
View filing
Mar 12, 2026
FY2025 · Annual results
EPS $-1.81 · Revenue $65343.00
View filing
Nov 10, 2025
Q3 FY2025 · Results reported
EPS $-0.87 · Revenue $0.00
View filing
Aug 12, 2025
Q2 FY2025 · Results reported
EPS $-0.61 · Revenue $0.00
View filing
May 13, 2025
Q1 FY2025 · Results reported
EPS $-725.11 · Revenue $65343.00
View filing

Financial Statements of INO

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$65343	-70.0%	—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-84.9M	+20.8%	+69.5%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+100.0%	0.0%	—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	-132871.3%	-157.4%	—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	-130000.0%	-163.9%	—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-88.9M	+15.0%	+16.4%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	-136074.5%	-183.4%	—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	38.9%	+124.5%	+27.8%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	1.40x	-49.5%	-3.8%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$74.3M	-34.4%	-0.8%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-1.81 vs -2.27	+20.3%	-0.07 vs -0.22	+67.7%
Revenue Surprise	$65343 vs $86000	-24.0%	$0 vs $533333	-100.0%

Insider Transactions of INO

Acquisitions (A)

Since May 20, 2026

Disposals (D)

Since May 20, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
May 20, 2026	YARNO WENDY L	director	Common Stock Options	A	41,800	$1.23
May 20, 2026	YARNO WENDY L	director	Restricted Stock Unit	A	34,200	—
May 20, 2026	Shepard Jay	director	Common Stock Options	A	41,800	$1.23
May 20, 2026	Shepard Jay	director	Restricted Stock Unit	A	34,200	—
May 20, 2026	Miller Ann Calby	director	Common Stock Options	A	41,800	$1.23

Earnings Call Transcript of INO

1 transcript segments

Q1 2026

Unknown Speaker

Operator: Good afternoon, ladies and gentlemen, and welcome to the Inovio First Quarter 2026 Financial Results Conference Call. [Operator Instructions] This call is being recorded on Wednesday, May 13, 2026. I would now like to turn the conference over to Jennie Willson. Please go ahead. Jennie Willson: Good afternoon, and thank you for joining the Inovio First Quarter 2026 Financial Results Conference Call. Joining me today on today's call are Dr. Jacqui Shea, President and Chief Executive Officer; Dr. Mike Sumner, Chief Medical Officer; Steve Egge, Chief Commercial Officer; and Peter Kies, Chief Financial Officer. Today's call will review our corporate and financial information for the quarter ended March 31, 2026, as well as provide a general business update. Following prepared remarks, we will conduct a question-and-answer segment. During the call, we will be making forward-looking statements regarding future events and the future performance of the company. These statements relate to our business plans to develop Inovio's DNA medicines platform, including the FDA's ongoing review of our BLA for INO-3107, including the October 30, 2026, PDUFA target date and our yet-to-be scheduled meeting with the FDA to discuss eligibility for the accelerated approval program, our belief that INO-3107 fulfills the criteria for accelerated approval; the potential benefits of INO-3107, including our belief that it has a positively differentiated product profile and the potential to become the preferred product by patients and their physicians, if approved; the anticipated commercial launch of INO-3107, if approved, and our engagement of commercial partners in preparation for a potential launch; our collaboration with Akeso Inc. to evaluate INO-5412 in combination with a novel dual checkpoint inhibitor for the potential treatment of GBM, the advancement of our DPROT technology platform, capital resources, including our estimated operational net cash burn of approximately $18 million for the second quarter of 2026 and the expected sufficiency of our cash resources into first quarter of 2027 and our expectations regarding competition, market size and acceptance of INO-3107 if approved. All of these statements are based on the beliefs and expectations of management as of today. Actual events or results could differ materially. We refer you to the documents we file from time to time with the SEC, which under the heading Risk Factors identify important factors that could cause actual results to differ materially from those expressed by the company verbally as well as statements made within this afternoon's press release. This call is being webcast live, and a link can be found on our website, ir.inovio.com, and a replay will be made available shortly after this call is concluded. I will now turn the call over to Inovio's President and CEO, Dr. Jacqui Shea. Jacqueline Shea: Good afternoon, and thank you to everyone for joining today's call. These are very busy …

Leadership Team of INO

10 executives

Name	Title	Compensation	Gender	Year Born	Status
Jacqueline E. Shea	Chief Executive Officer, President & Director	USD 889,099	—	1966	Active
Laurent Humeau	Chief Scientific Officer & Chairman of the Scientific Advisory Board	USD 794,082	—	1967	Active
Michael Sumner	Chief Medical Officer & Head of Development	USD 653,475	—	1965	Active
Peter D. Kies	Chief Financial Officer	USD 598,278	Male	1963	Active
Robert L. Crotty	General Counsel, Corporate Secretary & Chief Compliance Officer	—	Male	1974	Active
E. J. Brandreth	Senior Vice President of Quality Assurance	—	Male	—	Active
Robert J. Juba Jr.	Senior Vice President of Biological Manufacturing & Clinical Supply Management	—	Male	—	Active
Jeffrey Skolnik	Senior Vice President of Clinical Development	—	—	—	Active
Shawn D. Bridy	Senior Vice President of Business Development	—	Male	—	Active
Jennie Willson	Director of Communications	—	Female	—	Active

Recent News of INO

GuruFocus7/29/2026Neutral

INOVIO Announces Pricing of $20.0 Million Public Offering

INOVIO Announces Pricing of $20.0 Million Public Offering PR Newswire PLYMOUTH MEETING, Pa., July 29, 2026

PRNewsWire7/29/2026Neutral

INOVIO Announces Pricing of $20.0 Million Public Offering

PLYMOUTH MEETING, Pa., July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 21,052,632 shares of its common stock and accompanying warrants to purchase up to 42,105,264 shares of its common stock (or pre-funded warrants in lieu thereof) with an exercise price of $1.10 per share of common stock, at a combined public offering price of $0.95 per share of common stock and accompanying warrant to purchase two shares of common stock.

PRNewsWire7/29/2026Neutral

INOVIO Announces Proposed Public Offering

PLYMOUTH MEETING, Pa., July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof), in an underwritten public offering.

PRNewsWire6/4/2026Neutral

Kuehn Law Encourages Investors of Inovio Pharmaceuticals, Inc. to Contact Law Firm

NEW YORK, June 4, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Inovio Pharmaceuticals caused the company to misrepresent or fail to disclose that (i) manufacturing for Inovio's CELLECTRA device was deficient; (ii) accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (iv) accordingly, INO-3107's overall regulatory and commercial prospects were overstated.

Seeking Alpha6/4/2026Neutral

Inovio Pharmaceuticals, Inc. (INO) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Historical Employee Count of INO

Current

112

Change

-16.42%

Minimum

112

Maximum

317

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	112	10-K	Mar 12, 2026	View
Dec 31, 2024	134	10-K	Mar 18, 2025	View
Dec 31, 2023	122	10-K	Mar 6, 2024	View
Dec 31, 2022	184	10-K	Mar 1, 2023	View
Dec 31, 2021	317	10-K	Mar 1, 2022	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Inovio Pharmaceuticals, Inc.